Novartis has signed a long-term strategic partnership with Lonza to scale up the development and production of Novartis’ biologics pipeline.

Novartis has signed a long-term strategic partnership with Lonza to scale up the development and production of Novartis’ biologics pipeline.

The strategic partnership provides a win-win for both companies said  Mark Levick, global head of Novartis Biologics which will provide Novartis access to the most advanced technology and processes available to develop new biological medicines faster. It will also  allows Novartis to delay investments into manufacturing. Novartis also said it plans to expand its in-house manufacturing capabilities with a new facility in Singapore.

 The company currently has six biopharmaceutical manufacturing plants in Europe and the US.